Sobi's 2012 Long-Term Incentive programme meets all objectives

Swedish Orphan Biovitrum AB's (publ) (Sobi) Board of Directors today announced that the company's 2012 Long-Term Incentive programme met the objectives set and has vested in full. The total number of shares awarded to Sobi employees enrolled in the 2012 programme is 583,139.

---

More information about Sobi's 2012 long-term incentive programme can be found in Sobi's Annual Report 2014.

About Sobi
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.

 

For more information please contact

Media relations	Investor relations
Oskar Bosson, Head of Communications	Jörgen Winroth, Vice President, Head of Investor Relations
T: [phone]	T: [phone], [phone], [phone]
[e-mail]	[e-mail]

 

2012 LTI Vesting

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire

HUG#1927788